Samira kirjoitti: Ke Marras 02, 2022 2:20 pm
On Anoi Kaa kirjoitti: Ti Marras 01, 2022 12:15 pm
...
Tuolta pääset kiinni artikkeliin jonka kirjoittaja on
Editor and Chief of IPAK Journal of Science, Public Health Policy, and The Law,
Dr. James Lyons-Weiler ja näiden vertaisarvioituun tutkimukseen. Alleviivattuna pääkohdat:
https://twitter.com/Etrick/status/15873 ... cQKK4J69Pw
..
Wikipedia kertoo tutkimuksen tekijästä moista:
Lyons-Weiler has made numerous false and misleading claims about COVID-19 and vaccines.[2][3][4][5] United States Court of Federal Claims Special Master Christian J. Moran concluded in 2020 that Lyons-Weiler was "wholly unqualified to opine on the question of vaccine causation"; the decision related to a lawsuit in which Lyons-Weiler had testified claiming that a woman was injured as a result of the HPV vaccine.[2][6]
His February 2020 claim that SARS-CoV-2 contains a genetic sequence proving that the virus was probably engineered in a laboratory was discredited by researchers and fact-checkers.[7][8]
Samira kirjoitti: Ke Marras 02, 2022 2:20 pm
Minkä takia nää teidän lähteet on aina tällaista ripulia?
En minäkään ymmärrä miten te aina vain lätkäisette vasemmistoblogi wikipedian artikkelin jostain random-tyypistä ja yritätte sillä torpata
vertaisarvioidun tutkimuksen, mutta kaikki tavallaan. Ei siinnä.
Tuo
Lyons-Weiler on kirjoittanut siitä tutkimuksesta artikkelin, itse tutkimuksen tekijä on
Dr. Sin Hang Lee.
Kun sun mielestä tutkimus on silkkaa ripulia, eikö sun tulisi osoittaa miten tuo itse tutkija on tulkinnut käyttämiään lähteitä
vertaisarvioidussa tutkimuksessaan virheellisesti ja vituiksi?
Tutkimus:
https://www.publichealthpolicyjournal.c ... 40c143.pdf
Siinnä käytetyt lähteet:
Lu R, Zhao X, Li J, Niu P, Yang B, et al.
Genomic characterisation and epidemiology of
2019 novel coronavirus: Implications for virus
origins and receptor binding. Lancet. 2020;
395(10224):565-74.
Zhou P, Yang X L, Wang X G, Hu B, Zhang L,
et al. A pneumonia outbreak associated with a
new coronavirus of probable bat origin. Nature.
2020; 579(7798), 270–3.
Shang J, Wan Y, Luo C, Ye G, Geng Q, et al.
Cell entry mechanisms of SARS-CoV-2.
Proceedings of the National Academy of
Science. USA. 2020; 26;117(21):11727-34.
Coronavirus Updates. Worldometer. Available
online:
https://www.worldometers.info/coronavirus/
CDC. Severe Acute Respiratory Syndrome
(SARS). Available online:
https://www.cdc.gov/sars/about/faq.html
(accessed on 4 March 2022).
Abdelrahman Z, Li M, Wang X. Comparative
review of SARS-CoV-2, SARS-CoV, MERS-
CoV, and Influenza A respiratory viruses.
Frontiers in Immunology. 2020; 11:552909.
https://doi.org/10.3389/fimmu.2020.552909
Johansson M A, Quandelacy T M, Kada S,
Prasad P V, Steele M, et al. SARS-CoV-2
transmission from people without COVID-19
symptoms. JAMA Network Open. 2021; 4(1):
e2035057.
https://doi.org/10.1001/jamanetworkopen.2020
.35057
Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, et
al. Epidemiology and cause of severe acute
respiratory syndrome (SARS) in Guangdong,
People’s Republic of China, in February 2003.
Lancet. 2003;362(9393):1353–8.
https://doi.org/10.1016/s0140-6736(03)14630-
2
Drosten C, Preiser W, Günther S, Schmitz H,
Doerr HW. Severe acute respiratory syndrome:
identification of the etiological agent. Trends in
Molecular Medicine. 2003;9(8):325-7.
CDC. SARS-CoV Specific RT-PCR Primers.
Available online:
https://www.who.int/publications/m/item/sars-
cov-specific-rt-pcr-primers (accessed on 8 April
2022).
CDC SARS Response Timeline. Available
online:
https://www.cdc.gov/about/history/sars/timelin
e.htm (accessed on 4 June 2022).
Taleghani N, Taghipour F. Diagnosis of
COVID-19 for controlling the pandemic: A
review of the state-of-the-art. Biosensors &
Bioelectronics. 2021; 174: 112830.
https://doi.org/10.1016/j.bios.2020.112830
FDA. Nucleic Acid Amplification Assay for the
Detection of Enterovirus RNA – Class II
Special Controls Guidance for Industry and
FDA Staff.
https://www.fda.gov/medical-
devices/guidance-documents-medical-devices-
and-radiation-emitting-products/nucleic-acid-
amplification-assay-detection-enterovirus-rna-
class-ii-special-controls-guidance
FDA to CDC. Letter Dated 1 December 2020.
https://www.fda.gov/media/134919/download
Lee SH. Testing for SARS-CoV-2 in cellular
components by routine nested RT-PCR
followed by DNA sequencing. International
Journal of Geriatrics and Rehabilitation. 2020;
2: 69–96.
Lee SH. qPCR is not PCR just as a straightjacket
is not a jacket – The truth revealed by SARS-
CoV-2 false-positive test results. COVID-19
Pandemic: Case Studies & Opinions. 2021; 2:
230–78.
https://researchinfotext.com/article-
details/qPCR-is-not-PCR-Just-as-a-
Straightjacket-is-not-a-Jacket-the-Truth-
Revealed-by-SARS-CoV-2-False-Positive-
Test-Results
Kevadiya BD, Machhi J, Herskovitz J,
Oleynikov MD, Blomberg, et al. Diagnostics for
SARS-CoV-2 infections. Nature Materials.
2021; 20(5):593-605.
https://www.doi.org/10.1038/s41563-020-
00906-z
Loeffelholz MJ, Tang YW. Laboratory
diagnosis of emerging human coronavirus
infections – The state of the art. Emerging
Microbes & Infections. 2020; 9: 747–756.
Zheng L, Wang X, Zhou C, Liu Q, Li S, et al.
Analysis of the infection status of healthcare
workers in Wuhan during the COVID-19
outbreak: A cross-sectional study. Clinical
Infectious Diseases. 2020; 71:2109-2113.
https://www.doi.org/10.1093/cid/ciaa588
Liu R, Han H, Liu F, Lv Z, Wu K, et al. Positive
rate of RT-PCR detection of SARS-CoV-2
infection in 4880 cases from one hospital in
Wuhan, China, from Jan to Feb 2020. Clinica
Chimica Acta. 2020; 505:172-175.
https://www.doi.org/10.1016/j.cca.2020.03.009
Meng B, Abdullahi A, Ferreira IATM,
Goonawardane N, Saito A, et al. Altered
TMPRSS2 usage by SARS-CoV-2 Omicron
impacts infectivity and fusogenicity. Nature.
2022; 603: 706–714.
https://doi.org/10.1038/s41586-022-04474-x
McCallum M, Czudnochowski N, Rosen LE,
Zepeda SK, Bowen JE, et al. Structural basis of
SARS-CoV-2 Omicron immune evasion and
receptor engagement. Science. 2022; 375
(6583):864-868.
https://www.doi.org/10.1126/science.abn8652
VanBlargan L A, Errico JM, Halfmann P J,
Zost S J, Crowe J E Jr, et al. An infectious
SARS-CoV-2 B.1.1.529 Omicron virus escapes
neutralization by therapeutic monoclonal
antibodies. Nature Medicine. 2022; 28:490–
495.
https://doi.org/10.1038/s41591-021-01678-y
McCarthy K R, Rennick L J, Nambulli S,
Robinson-McCarthy L R, Bain W G, et al.
Recurrent deletions in the SARS-CoV-2 spike
glycoprotein drive antibody escape. Science.
2021; 371: 1139–1142.
https://doi.org/10.1126/science.abf6950
Lee SH. A routine Sanger sequencing target
specific mutation assay for SARS-CoV-2
variants of concern and interest. Viruses. 2021;
13: 2386.
https://doi.org/10.3390/v13122386
CDC. SARS-CoV-2 Variant Classifications and
Definitions. Available online:
https://www.cdc.gov/coronavirus/2019-
ncov/variants/variant-info.html
ECDC. Implications of the emergence and
spread of the SARS-CoV-2 B.1.1. 529 variant
of concern (Omicron) for the EU/EEA. 26
November 2021.
https://www.ecdc.europa.eu/sites/default/files/
documents/Implications-emergence-spread-
SARS-CoV-2%20B.1.1.529-variant-concern-
Omicron-for-the-EU-EEA-Nov2021.pdf
CoV-lineages Github. Proposal to split
B.1.1.529 to incorporate a newly characterised
sibling lineage #361.
https://github.com/cov-lineages/pango-
designation/issues/361
Lee SH. Lyme disease caused by Borrelia
burgdorferi with two homeologous 16S rRNA
genes: A case report. International Medical
Case Reports Journal. 2016; 9: 101–106.
https://doi.org/10.2147/IMCRJ.S99936
Walker A, Houwaart T, Wienemann T,
Vasconcelos MK, Strelow D, et al. Genetic
structure of SARS-CoV-2 reflects clonal
superspreading and multiple independent
introduction events, North-Rhine Westphalia,
Germany, February and March 2020.
Eurosurveillance. 2020; 25(22):2000746.
Gupta K, Toelzer C, Williamson MK,
Shoemark DK, Oliveira ASF, et al. Structural
insights in cell-type specific evolution of intra-
host diversity by SARS-CoV-2. Nature
Communications. 2022; 13(1): 222.
https://doi.org/10.1038/s41467-021-27881-6
Wang Y, Wang D, Zhang L, Sun W, Zhang Z,
et al. Intra-host variation and evolutionary
dynamics of SARS-CoV-2 populations in
COVID-19 patients. Genomic Medicine. 2021;
13(1): 30.
https://doi.org/10.1186/s13073-021-00847-5
Mushegian AA, Long SW, Olsen RJ,
Christensen PA, Subedi S, et al. Within-host
genetic diversity of SARS-CoV-2 in the context
of large-scale hospital-associated genomic
surveillance. medRxiv preprint. 2022.
https://doi.org/10.1101/2022.08.17.22278898
Shagin DA, Lukyanov KA, Vagner LL, Matz
MV. Regulation of average length of complex
PCR product. Nucleic Acids Research. 1999;
27(18):e23.
Appenzeller, T. Democratizing the DNA
sequence. Science. 1990; 247: 1030-1032.
Kwok S, Kellogg DE, McKinney N, Spasic D,
Goda L, et al. Effects of primer-template
mismatches on the polymerase chain reaction:
human immunodeficiency virus type 1 model
studies. Nucleic Acids Research. 1990; 18(4):
999-1005.
O'Dell SD, Humphries SE, Day IN. PCR
induction of a TaqI restriction site at any CpG
dinucleotide using two mismatched primers
(CpG-PCR). Genome Research. 1996; 6:558-
68.
https://doi.org/10.1101/gr.6.6.558
Ruiz-Villalba A, van Pelt-Verkuil E, Gunst QD,
Ruijter JM, van den Hoff MJ. Amplification of
nonspecific products in quantitative polymerase
chain reactions (qPCR). Biomolecular
Detection and Quantification. 2017; 14:7-18.
https://doi.org/10.1016/j.bdq.2017.10.001
Stadhouders R, Pas SD, Anber J, Voermans J,
Mes TH, et al. The effect of primer-template
mismatches on the detection and quantification
of nucleic acids using the 5' nuclease assay.
Journal of Molecular Diagnostics. 2010;
12(1):109-17.
https://doi.org/10.2353/jmoldx.2010.090035
Ryu KH, Choi SH, Lee JS. Restriction primers
as short as 6-mers for PCR amplification of
bacterial and plant genomic DNA and plant
viral RNA. Molecular Biotechnology. 2000: 14:
1–3.
FDA. In Vitro Diagnostics EUAs. Molecular
Diagnostic Template for Laboratories.
https://www.fda.gov/medical-
devices/coronavirus-disease-2019-covid-19-
emergency-use-authorizationsmedical-
devices/vitro-diagnostics-euas (accessed on 19
January 2021).
Narayanan S, Ritchey JC, Patil G, Narasaraju T,
More S, et al. SARS-CoV-2 Genomes from
Oklahoma, United States. Frontiers in Genetics.
2021;11:612571.
https://doi.org/10.3389/fgene.2020.612571
Callaway E. Beyond Omicron: What’s next for
COVID's viral evolution. Nature. 2021; 600
(7888):204–207.
https://doi.org/10.1038/d41586-021-03619-8
Li J, Du P, Yang L, Zhang J, Song C, et al. Two-
step fitness selection for intra-host variations in
SARS-CoV-2. Cell Reports. 2022; 38(2):
110205.
https://www.doi.org/10.1016/j.celrep.2021.110
205
Vignuzzi M, Stone JK, Arnold JJ, Cameron CE,
Andino R. Quasispecies diversity determines
pathogenesis through cooperative interactions
in a viral population. Nature. 2006; 439(7074):
344-8.
https://www.doi.org/10.1038/nature04388
Poon LL, Song T, Rosenfeld R, Lin X, Rogers
MB, et al. Quantifying influenza virus diversity
and transmission in humans. Nature Genetics.
2016; 48(2):195-200.
https://www.doi.org/10.1038/ng.3479
To KK, Chan JF, Chen H, Li L, Yuen KY. The
emergence of influenza A H7N9 in human
beings 16 years after influenza A H5N1: A tale
of two cities. Lancet Infectious Diseases. 2013;
13(9):809-21.
https://www.doi.org/10.1016/S1473-
3099(13)70167-1
Higuchi R, Fockler C, Dollinger G, Watson R.
Kinetic PCR analysis: Real-time monitoring of
DNA amplification reactions. Biotechnology.
1993; 11: 1026-1030.
Svec D, Tichopad A, Novosadova V, Pfaffl
MW, Kubista M. How good is a PCR efficiency
estimate: Recommendations for precise and
robust qPCR efficiency assessments. Bio-
molecular Detection and Quantification. 2015;
3:9-16.
https://www.doi.org/10.1016/j.bdq.2015.01.00
5
Azadeh M, Sondag P, Wang Y, Raines M,
Sailstad J. Quality controls in ligand binding
assays: Recommendations and best practices for
preparation, qualification, maintenance of lot to
lot consistency, and prevention of assay drift.
AAPS Journal. 2019; 21(5):89.
https://www.doi.org/10.1208/s12248-019-
0354-6
Centers for Disease Control & Prevention,
Poxvirus & Rabies Branch (PRB). Test
procedure: Monkeypox virus generic real-time
PCR test.
https://www.cdc.gov/poxvirus/monkeypox/pdf/
pcr-diagnostic-protocol-508.pdf
CDC. 2019-Novel Coronavirus (2019-nCoV)
real-time RT-PCR diagnostic panel:
Instructions for use.
https://www.fda.gov/media/134922/download
WHO. Information notice for IVD users –
Nucleic acid testing (NAT) technologies that
use real-time polymerase chain reaction (RT-
PCR) for detection of SARS-CoV-2.
https://www.who.int/news/item/14-12-2020-
who-information-notice-for-ivd-users
(Accessed 20 February, 2021.)
Archived at:
https://bit.ly/3zIYJVZ
Paltiel AD, Zheng A, Walensky RP.
Assessment of SARS-CoV-2 screening
strategies to permit the safe reopening of college
campuses in the United States. JAMA Network
Open. 2020; 3(7):e2016818. Published 2020, 1
Jul.
https://www.doi.org/10.1001/jamanetworkopen
.2020.16818
Pfizer Inc. PF-07302048 (BNT162 RNA-Based
COVID-19 Vaccines) Protocol C4591001
https://cdn.pfizer.com/pfizercom/2020-
11/C4591001_Clinical_Protocol_Nov2020.pdf
Pfizer Inc. Pfizer and BioNTech conclude Phase
3 study of COVID-19 vaccine candidate,
meeting all primary efficacy endpoints.
https://www.pfizer.com/news/press-
release/press-release-detail/pfizer-and-
biontech-conclude-phase-3-study-covid-19-
vaccine
ECDC and WHO Regional Office for Europe.
Methods for the detection and characterisation
of SARS-CoV-2 variants – First update.
https://www.ecdc.europa.eu/en/publications-
data/methods-detection-and-characterisation-
sars-cov-2-variants-first-update
WHO. Tracking SARS-CoV-2 variants.
https://www.who.int/activities/tracking-SARS-
CoV-2-variants
Lee, S. Sanger sequencing for molecular
diagnosis of SARS-CoV-2 Omicron subvariants
and its challenges. Journal of Biosciences and
Medicines. 2022; 10: 182-223.
https://www.doi.org/10.4236/jbm.2022.109015
Clarke AE, Casper MJ. From simple technology
to complex arena: Classification of Pap smears,
1917-90. Medical Anthropology Quarterly.
1996; 10:601-23.